The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.Nature medicine · 2024
   Pooled it
2. Dietary niacin intake and mortality outcomes in hypertensive populations: analysis from NHANES 2003-2016.Journal of health, population, and nutrition · 2025
   Article
3. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Drugs · 2015
   Review
4. HDL-targeted therapies: progress, failures and future.Nature reviews. Drug discovery · 2014
   Review
5. HDL hypothesis: where do we stand now?Current atherosclerosis reports · 2014
   Review

Corrections and comments

• Comment on
  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as